Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Koji Nishijima is active.

Publication


Featured researches published by Koji Nishijima.


Journal of Bone and Mineral Metabolism | 1999

Intestinal absorption of calcium from calcium ascorbate in rats

Naoko Tsugawa; Takashi Yamabe; Atsuko Takeuchi; Maya Kamao; Kimie Nakagawa; Koji Nishijima; Toshio Okano

Abstract: The intestinal absorption of calcium (Ca) from Ca ascorbate (Ca-AsA) was investigated in normal rats. Each animal was perorally administered either 5 mg (low dose) or 10 mg (high dose) of Ca in 1 ml of distilled water as Ca-AsA, Ca carbonate (CaCO3), or Ca chloride (CaCl2), which were intrinsically labeled with 45Ca using 45CaCl2. The amount of radioactivity in plasma was measured periodically up to 34 h after dosing, and pharmacokinetic parameters were calculated from the radioactivity in plasma. The time taken to reach the maximum 45Ca level (Tmax) did not differ among the three groups. The area under the plasma 45Ca level/time curve (AUC∞) value for the Ca-AsA group was significantly higher than those for the CaCO3 and the CaCl2 groups. The radioactivity at Tmax (Cmax) for the Ca-AsA group was significantly higher than those for the CaCO3 and the CaCl2 groups for the low dose, and comparable with or significantly higher than those for the CaCl2 and CaCO3 groups for the high dose. Similar results were observed for whole-body 45Ca retention. Radioactivity in the femur 34 h after dosing was the highest in the Ca-AsA group and the lowest in the CaCO3 group. The rank order of solubility in water, the first fluid (pH 1.2, JP-1) of JPXIII disintegration medium, acetate buffer solution (pH 4.0), triethanolamine-malate buffer solution (pH 7.0) and ammonium chloride buffer solution (pH 10.0) at 37°C was CaCl2 > Ca-AsA > CaCO3. In contrast, the rank order of the solubility in the second fluid (pH 6.8, JP-2) of JPXIII disintegration medium at 37°C was Ca-AsA > CaCl2 > CaCO3. These results indicate that the absorbability of Ca from Ca-AsA is almost comparable with, or higher than, that from CaCl2 and significantly higher than that from CaCO3 because of its high degree of solubility in the intestine. Therefore, Ca-AsA would be useful as a Ca supplement with relatively high absorption from intestine.


Chemical & Pharmaceutical Bulletin | 1999

Determination of Free Fatty Acids in o/w Injectable Emulsions by HPLC with Fluorescence Detection Using 4-(N,N-Dimethylaminosulfonyl)-7-N- piperazino-2,1,3-benzoxadiazole

Yumiko Ueno; Hirokazu Matsunaga; Kazuichi Umemoto; Koji Nishijima


Archive | 1974

Process for producing α-sulfophenylacetic acid derivatives

Keiichi Sugimoto; Koji Nishijima; Hiroshi Akimoto; Tadashi Hanaoka; Nobuharu Kakeya


Journal of Labelled Compounds and Radiopharmaceuticals | 1975

Synthesis of disodium D (-)-6-(2-phenyl-2-sulfoacetamido-1-14C) penicillanate (sulfocillln-14C) and 6-(2-isobutyl-β,γ-3H2-sulfo-2-phenylacetamido-1-14C) penicillanic acid (SP-421-3H, 14C)

Nobuyoshi Haayshi; Shinji Kato; Tadashi Toga; Koji Nishijima; Tadashi Hanaoka; Hiroshi Akimoto; Keiichi Sugimoto


Journal of the Pharmaceutical Society of Japan | 1998

Stability Study of Cefozopran Monohydrochloride Using Non-Isothermal Method

Hirokazu Matsunaga; Sohachiro Miyake; Koji Nishijima


Archive | 1976

d-α-Isobutylsulfobenzylpenicillin hemi-solvate crystals

Keiichi Sugimoto; Koji Nishijima; Tadashi Hanaoka; Hiroshi Akimoto; Nobuharu Kakeya


Archive | 1973

α-Alkylsulfobenzyl penicillins

Keiichi Sugimoto; Koji Nishijima; Hiroshi Akimoto; Tadashi Hanaoka; Nobuharu Kakeya


Archive | 1976

D-alpha-isobutylsulfobenzylpenicillin- hemisolvatkristalle und verfahren zu ihrer herstellung D-alpha-isobutylsulfobenzylpenicillin- hemisolvatkristalle and process for their manufacture

Keiichi Sugimoto; Koji Nishijima; Tadashi Hanaoka; Hiroshi Akimoto; Nobujaru Kakeyo


Archive | 1976

D-alpha-isobutylsulfobenzylpenicillin- hemisolvatkristalle and processes for their preparation

Keiichi Sugimoto; Koji Nishijima; Tadashi Hanaoka; Hiroshi Akimoto; Nobujaru Kakeyo


Archive | 1976

D-alpha-isobutylsulfobenzylpenicillin- hemisolvatkristalle und verfahren zu ihrer herstellung

Keiichi Sugimoto; Koji Nishijima; Tadashi Hanaoka; Hiroshi Akimoto; Nobujaru Kakeyo

Collaboration


Dive into the Koji Nishijima's collaboration.

Top Co-Authors

Avatar

Keiichi Sugimoto

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Tadashi Hanaoka

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Hiroshi Akimoto

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Nobuharu Kakeya

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Hirokazu Matsunaga

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Atsuko Takeuchi

Kobe Pharmaceutical University

View shared research outputs
Top Co-Authors

Avatar

Kazuichi Umemoto

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Kimie Nakagawa

Kobe Pharmaceutical University

View shared research outputs
Top Co-Authors

Avatar

Maya Kamao

Kobe Pharmaceutical University

View shared research outputs
Top Co-Authors

Avatar

Naoko Tsugawa

Kobe Pharmaceutical University

View shared research outputs
Researchain Logo
Decentralizing Knowledge